In the second of two blogs in a collaborative series written by Paul Evans, President and CEO, and Victoria DiBiaso, Head, Patient Informed Development & Health Value Translation, Sanofi, they emphasize the most critical aspect of clinical trials — the patient. As we blaze a trail toward faster and more efficient clinical trials, it is … Read more
“Clinical research is really the only opportunity we have to give our patients some hope and some perspective that their disease will one day be treatable.” Nadege Gunn, MD, CPI, DABOM, FAASLD, has consistently championed community engagement and physician referrals to drive successful clinical trial enrollment at her site in Waco, TX. As a MASH … Read more
Congratulations to Paul Evans, President and CEO of Velocity, for being named one of the most influential life sciences business leaders in the state in Business North Carolina’s 2024 Power List! The list was compiled by BNC’s editorial team after seeking nominations, talking with dozens of sources, and performing extensive research. Well done, Paul! Read … Read more
Merck recently presented Velocity’s Hallandale Beach site with the Significant Contribution to Clinical Trials Award, specifically for being the top enroller of diverse participants in cardiovascular clinical trials in 2023. We’re grateful for the contributions of our Hallandale Beach site toward improving diversity in clinical trials, both in the workforce and in our participants. We’re … Read more
Velocity recently asked some key employees to come together and discuss a wide array of issues impacting health equity in trials. Velocity’s ongoing goals are to share best practices, identify and address shortcomings, and bring as many perspectives and viewpoints to the table as possible to advance clinical trials and deliver vital new drugs and … Read more
To celebrate the upcoming Clinical Trials Day and the ‘Trailblazers Among Us’ theme, Paul Evans, President and CEO of Velocity, and Victoria DiBiaso, Head, Patient Informed Development & Health Value Translation at Sanofi, have coauthored this article. In the post, they review several of the opportunities and challenges inherent in shaping a better future for … Read more
Shishir Khetan, MD, is a Principal Investigator and Senior Medical Director at Velocity. He’s also a leading expert for the Cardiometabolic CARE Council. But as he explains in this video, he’s excited about the opportunities the CARE Council model is creating for investigators. Through expert knowledge exchange — including mentoring and training opportunities provided by … Read more
Heart disease remains the leading cause of death worldwide. The proliferation of heart issues — paired with lifestyle factors that complicate patient recruitment and study design — reflect an urgent need for expert-led clinical trials. Moreover, intersections among heart health and metabolic research offer promising opportunities to confront diseases affecting a growing, aging population, and … Read more
The global prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) is rising. In light of the stark unmet needs in liver disease treatment — particularly for metabolic dysfunction-associated steatohepatitis (MASH) — there’s a pressing need for more sites equipped to effectively support advanced liver disease research. As Kris Kowdley, MD, AGAF, FAASLD, FACP, FACG, mentions … Read more
Velocity recently asked some key employees to come together and discuss a wide array of issues impacting health equity in clinical trials. Velocity’s ongoing goals are to share best practices, identify and address shortcomings, and bring as many perspectives and viewpoints to the table as possible to advance clinical trial science and deliver vital new … Read more